MUMBAI:
Tatva Chintan Pharma Chem Limited, a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents, phase transfer catalysts, electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals, allotted 13,85,040 equity shares to 22 anchor investors and raised ₹149.99 crore ahead of the company’s proposed IPO at the upper price band of ₹1,083 per equity share.
Out of the total anchor allocation, 47% was allocated to mutual funds, including Axis MF, ICICI Prudential MF and HDFC MF. Significant FII participants included Abu Dhabi Investment Authority, Aberdeen Standard Investments, Goldman Sachs and Nomura Ireland.
The Offer comprises a fresh issue of such number of Equity Shares aggregating up to ₹2,250.00 million and an offer for sale of up to aggregating up to ₹2,750.00 million.
Bids can be made for a minimum of 13 Equity Shares and in multiples of 13 Equity Shares thereafter. ICICI Securities Limited and JM Financial Limited are the book running lead managers (“BRLMs”) to the Offer.
